Macrophage Activation Syndrome Epidemiology Forecast 2026-2035

Macrophage activation syndrome (MAS) is a rare, life-threatening hyperinflammatory condition occurring as a severe complication of rheumatic and autoinflammatory diseases. According to Arthur Dilibe et al., 2024, its incidence is estimated at 0.16-0.4 per 100,000 inhabitants with a prevalence of 1-24 per million worldwide, and it often affects adults aged 27-36 years. As per the macrophage activation syndrome epidemiology forecast, MAS case numbers in major markets are projected to rise through 2034, reflecting increased autoimmune and inflammatory disease burden.

Macrophage Activation Syndrome Epidemiology Forecast Report Coverage

The analyst's “Macrophage Activation Syndrome Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of macrophage activation syndrome. It projects the future incidence and prevalence rates of macrophage activation syndrome cases across various populations. The study covers age, gender, and type as major determinants of the macrophage activation syndrome population. The report highlights patterns in the prevalence of macrophage activation syndrome over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of macrophage activation syndrome in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Macrophage Activation Syndrome Understanding: Disease Overview

Macrophage activation syndrome (MAS) is a severe, potentially life-threatening hyperinflammatory disorder characterized by excessive activation and proliferation of macrophages and T lymphocytes. It is considered a secondary form of hemophagocytic lymphohistiocytosis and most commonly occurs in patients with systemic autoimmune or autoinflammatory diseases, particularly systemic juvenile idiopathic arthritis and systemic lupus erythematosus. MAS develops due to impaired immune regulation, leading to a cytokine storm, multiorgan dysfunction, cytopenias, liver impairment, and coagulopathy. It is primarily classified as secondary hemophagocytic lymphohistiocytosis associated with rheumatologic conditions.

Macrophage Activation Syndrome Epidemiology Perspective

The macrophage activation syndrome epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for macrophage activation syndrome epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for macrophage activation syndrome and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Arthur Dilibe et al., 2023, macrophage activation syndrome is a rare and severe complication of systemic juvenile idiopathic arthritis and adult-onset Still’s disease. The estimated global incidence ranges from 0.16 to 0.40 per 100,000 inhabitants, with a prevalence of 1 to 24 per million.
• As per Arthur Dilibe et al., 2023, the disease shows age-related variation based on its underlying disorders. The median age at diagnosis ranges from 27 to 36 years in adult-onset Still’s disease, while it occurs in patients diagnosed with systemic juvenile idiopathic arthritis before 16 years of age.
• According to Veghini DM et al., 2023, Macrophage Activation Syndrome occurs in over 10% of adult-onset Still’s disease cases. The mortality rate in patients with adult-onset Still’s disease complicated by macrophage activation syndrome is 52.9%, compared to 9.5% without this complication.
• As per Leila Barakat et al., 2025, in systemic lupus erythematosus-associated macrophage activation syndrome, the average patient age was 26 years, with a marked female predominance (7 women and 1 man). Mortality was reported in 25% of cases, despite intensive immunosuppressive treatment.

Country-wise Macrophage Activation Syndrome Epidemiology

The macrophage activation syndrome epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Macrophage activation syndrome epidemiology across the regions reflects its close association with underlying rheumatologic conditions, particularly adult-onset Still’s disease. According to Iman A. A. Shaat et al., 2025, the incidence of adult-onset Still’s disease in the United States ranges from 0.16 to 0.4 per 100,000 population annually, with a five-year inpatient mortality rate of 2.6%. As per Raja Bakhsh et al., 2025, prevalence estimates range from 0.73 to 6.77 per 100,000, while Japan reports approximately 3.9 per 100,000, indicating notable regional variation across these reported markets.

Macrophage Activation Syndrome: Treatment Overview

The treatment of macrophage activation syndrome focuses on rapid suppression of the hyperinflammatory response and management of the underlying disease. High-dose corticosteroids are considered first-line therapy to control immune overactivation. In refractory or severe cases, immunosuppressive agents such as cyclosporine and biologic therapies targeting interleukin-1 or interleukin-6 are administered. Etoposide may be considered in life-threatening cases resembling hemophagocytic lymphohistiocytosis. Supportive care, including blood product transfusions and intensive care monitoring, is essential to manage organ dysfunction and prevent complications. Early recognition and prompt intervention can significantly improve clinical outcomes.

Key Questions Answered

• What are the key findings of macrophage activation syndrome epidemiology in the 8 major markets?
• What will be the total number of patients with macrophage activation syndrome across the 8 major markets during the forecast period?
• What was the country-wise macrophage activation syndrome epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of macrophage activation syndrome patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of macrophage activation syndrome during the forecast period of 2026-2035?
• What are the currently available treatments for macrophage activation syndrome?
• What are the risks, signs, symptoms, and unmet needs of macrophage activation syndrome?

Scope of the Macrophage Activation Syndrome Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of macrophage activation syndrome based on several factors.
• Macrophage Activation Syndrome Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The macrophage activation syndrome report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.